Profit before interest, taxes and amortization: Chimerix (CMRX)

Graphic logo of Chimerix (CMRX)

Chimerix, Inc. (CMRX) seeks molecular methods for treating rare pathologies and cancer where conventional medicine is ineffective. The EBITDA trend reflects sharp cash flow spikes, with the mark recording this indicator. Strict FDA regulations and a staff of virologists ensure stability, while the environmental profile is limited to laboratory safety.

Chimerix, Inc. (CMRX) - Operating profit EBITDA from 07/04/2022 to 11/10/2026

Summary analytical data breakdowns for Chimerix (CMRX)

- stock quotes and analyst forecast:
Price Performance Chart Chimerix Inc|CMRX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Chimerix|CMRX - Total Company Value
- book capitalization data:
Equity per Share Chimerix|CMRX - Book Capitalization|Market Cap to Net Assets Ratio chimerix.com|CMRX - Aggregate Company Assets
- debt level and financial liquidity data:
Debt to Capital Chimerix, Inc.|CMRX - Long-Term Debt to Equity|Short-Term Debt to Equity Chimerix Inc.|CMRX - Company Debts|Debts to Book Value Chimerix|CMRX - Company Long-Term Debts|Short-Term Indebtedness Chimerix|Immediate Liquidity chimerix.com
- earnings and valuation multiples indicators:
CMRX - Net Income|Expected Net Income Chimerix, Inc.|CMRX - Price to Earnings Ratio|Market Cap to Future Earnings Ratio chimerix.com|CMRX - PEG Multiple|Business Value to Operating Income Before Depreciation Chimerix|CMRX - Operating profit EBITDA|Net earnings per one share for the last twelve months Chimerix|CMRX - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months chimerix.com|CMRX - Earnings growth in current year|Earnings growth forecast for next year Chimerix, Inc.
Analysis of all company metrics:Chimerix, Inc.
Manufactured product of Chimerix Inc.

As a biotech developer in the oncology sector with the unique status of TEMBEXA in the US Strategic National Stockpile, Chimerix, Inc. (CMRX) depends on liquidity inflows to advance ONC201 therapy. This metric measures the actual volume of cash from core operations before depreciation and taxes, allowing GURU.Markets to assess the company's ability to fund innovation without external loans via the current EBITDA level.

Who Chimerix, Inc. competes with

Income before deduction of interest, taxes and amortization INCY|HCM - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization nuvationbio.com|Day One Biopharmaceuticals (DAWN) - Profit before payment of interest, taxes and amortization|Operating profit before amortization MNPR|INBX (Inhibrx Biosciences Inc) - Operating profit EBITDA|Operating profit before deduction of amortization I-Mab Inc. (IMAB)|Profit before payment of interest, taxes and amortization Fennec Pharmaceuticals (FENC)|HRTX - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Nuvectis Pharma NVCT|Coherus - Profit before payment of interest, taxes and amortization|CRBP - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Cardiff Oncology, Inc.|BYSI: Operating profit EBITDA|Operating profit before depreciation charges BioAtla BCAB|Operating profit before deduction of amortization LIXT|Profit before interest, taxes and amortization Citius Pharma CTXR|Operating profit before deduction of amortization CLRB (Cellectar)|BLRX (BioLineRx Corporation) - Income before deduction of interest, taxes and amortization|Can-Fite BioPharma - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization APRE (Aprea Therapeutics Inc.)|Kazia - Operating profit EBITDA|Income before deduction of interest, taxes and amortization SLXN (Silexion Therapeutics Corp)|NCNA: Operating profit EBITDA|Profit before interest, taxes and amortization Cyclacel, Inc. (CYCC)|Profit before payment of interest, taxes and amortization G1 Therapeutics Inc.|KRON: Income before deduction of interest, taxes and amortization|Operating profit EBITDA KTRA|Operating profit EBITDA Oncternal Therapeutics Inc (ONCT)|Profit before payment of interest, taxes and amortization Portage PRTG